← 返回

用于癌症治疗的 NK 细胞疗法开发策略

英文原题:Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.

查看英文原题

Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.

PubMed 2025/11/25(内容时间) Cells Q2 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

CAR-T 细胞疗法是一种有前景的癌症治疗方法,但它存在一些缺点。这些缺点促使科学家探索使用更安全的CAR-NK细胞和新的基因修饰,以提高CAR细胞的有效性。在本文中,我们分析了现有的CAR-NK细胞修饰方法,并讨论了涉及CAR-NK疗法的临床试验结果。通常,NK细胞修饰的方法可分为三大类:增强抗肿瘤细胞毒性的策略、改善CAR-NK细胞存活并延长其在体内持续存在的策略,以及提高CAR-NK细胞安全性的策略。本文介绍了CAR-NK细胞对不同肿瘤类型的作用,涉及CAR-NK细胞的临床试验数量逐年增加,迄今为止结果积极。截至2025年9月,所有试验均处于1-2期研究的早期阶段,预计首个CAR-NK产品将在不久的将来获得批准。

展开英文摘要原文

CAR-T cell therapy is a promising method of cancer treatment, but it has some disadvantages. These disadvantages have led scientists to explore the use of safer CAR-NK cells and new genetic modifications in order to improve the effectiveness of CAR cells. In this paper, we analyze existing approaches to modifying CAR-NK cells and discuss the results of clinical trials involving CAR-NK therapies.

Conventionally, approaches to NK cell modification can be divided into three main groups: strategies to enhance antitumor cytotoxicity, strategies to improve the survival of CAR-NK cells and prolong their persistence in the body, and strategies to increase the safety of CAR-NK cells.

The effects of CAR-NK cells on different tumor types are presented, and the number of clinical trials involving CAR-NK cells has been increasing every year, with positive results so far. As of September 2025, all the trials are in the early 1-2 stages of research, and it is expected that the first CAR-NK product will be approved in the near future.

论文信息

作者
Budagova T、Efremova A、Maiak M、Goldshtein D
单位
Federal State Budgetary Scientific Institution Research Centre for Medical Genetics, Moskvorechye Str. 1, Moscow 115522, Russia.Russia
文献类型
综述 · 非美国政府资助研究
期刊
Cells2025 Nov 25
原文标识
PubMed 41369346 · DOI 10.3390/cells14231858